TB-500 Research Peptides

Compare TB-500 research products by labelled quantity, price per mg, testing evidence and product transparency. Read what the direct evidence actually shows for tendon and wound research, how TB-500 differs from full-length thymosin beta-4, and what remains unknown in humans.

Research-use products only. Not presented as supplements, medicines, or products for human or veterinary consumption.

4products compared

2labelled quantities

£2.50 – £8.00per mg

1with verified testing evidence

Top Picks

Best Overall

Quantity: 5 mg / vial

£4.80per mg

£23.99per pack

View Analysis Buy Now

Product & testing details

Supplier: UK Peptides (ukpeptides.org)
Vials per pack: 1
Price per vial: £23.99
Listing last checked: 2026-09-20 09:20:11

Evidence status: Manufacturer COA
Manufacturer statement: Independent third-party laboratory report for batch UKP-TB500-2511 of TB-500 5mg, issued by an accredited independent laboratory using HPLC-UV + Mass Spectrometry. Result: ≥98{4126ccafc2fa8f847ceaeb6a91497cc67cd381373337e0df85dd9df95f3d94fa} HPLC.
Laboratory: Not recorded
Certification body: Not recorded
Batch: UKP-TB500-2511
Batch-specific report: Recorded
Report date: 2025-11-25
Evidence checked: 2026-09-20

Certificate of analysis ↗

TB-500 5mg

UK Peptides (ukpeptides.org)

£4.80per mg

£23.99per pack

View Analysis Buy Now

Best Tested

Quantity: 5 mg / vial

£4.80per mg

£23.99per pack

View Analysis Buy Now

Product & testing details

Supplier: UK Peptides (ukpeptides.org)
Vials per pack: 1
Price per vial: £23.99
Listing last checked: 2026-09-20 09:20:11

Evidence status: Manufacturer COA
Manufacturer statement: Independent third-party laboratory report for batch UKP-TB500-2511 of TB-500 5mg, issued by an accredited independent laboratory using HPLC-UV + Mass Spectrometry. Result: ≥98{4126ccafc2fa8f847ceaeb6a91497cc67cd381373337e0df85dd9df95f3d94fa} HPLC.
Laboratory: Not recorded
Certification body: Not recorded
Batch: UKP-TB500-2511
Batch-specific report: Recorded
Report date: 2025-11-25
Evidence checked: 2026-09-20

Certificate of analysis ↗

TB-500 5mg

UK Peptides (ukpeptides.org)

£4.80per mg

£23.99per pack

View Analysis Buy Now

Lowest Price per mg

Quantity: 10 mg / vial

£2.50per mg

£25.00per pack

View Analysis Buy Now

Product & testing details

Supplier: Reta Research
Vials per pack: 1
Price per vial: £25.00
Listing last checked: 2026-09-20 09:20:11

Evidence status: Testing claimed
Manufacturer statement: Lyophilised powder, 10mg vial, ≥99{4126ccafc2fa8f847ceaeb6a91497cc67cd381373337e0df85dd9df95f3d94fa} purity by HPLC, Certificate of Analysis on request. UK-based dispatch for preclinical research only.
Laboratory: Not recorded
Certification body: Not recorded
Batch: Not recorded
Batch-specific report: Not established in this record
Report date: Not recorded
Evidence checked: 2026-09-20

TB-500 10mg

Reta Research

£2.50per mg

£25.00per pack

View Analysis Buy Now

Compare research products

Vial size

Research peptide product comparison
#	Product	Quantity	Price / vial	Price / mg	Testing	Score
1	TB-500 5mgUK Peptides (ukpeptides.org)	5 mg / vial	£23.99per vial	£4.80per mg	Testing evidence Evidence status Manufacturer COA Manufacturer statement Independent third-party laboratory report for batch UKP-TB500-2511 of TB-500 5mg, issued by an accredited independent laboratory using HPLC-UV + Mass Spectrometry. Result: ≥98{4126ccafc2fa8f847ceaeb6a91497cc67cd381373337e0df85dd9df95f3d94fa} HPLC. Laboratory Not recorded Certification body Not recorded Batch UKP-TB500-2511 Batch-specific report Recorded Report date 2025-11-25 Evidence checked 2026-09-20 Certificate of analysis ↗	Why this score? Testing & analytical evidence 38/45 Value 15/25 Product identity 11/15 Supplier transparency 10/10 Label & listing transparency 5/5 Displayed points and weights are rounded; the total uses unrounded weights. Pending dimensions are excluded. Provisional scores may change after review.	Buy Now
2	TB-500 10mgReta Research	10 mg / vial	£25.00per vial	£2.50per mg	Testing evidence Evidence status Testing claimed Manufacturer statement Lyophilised powder, 10mg vial, ≥99{4126ccafc2fa8f847ceaeb6a91497cc67cd381373337e0df85dd9df95f3d94fa} purity by HPLC, Certificate of Analysis on request. UK-based dispatch for preclinical research only. Laboratory Not recorded Certification body Not recorded Batch Not recorded Batch-specific report Not established in this record Report date Not recorded Evidence checked 2026-09-20	Why this score? Testing & analytical evidence 12/45 Value 24/25 Product identity 12/15 Supplier transparency 10/10 Label & listing transparency 5/5 Displayed points and weights are rounded; the total uses unrounded weights. Pending dimensions are excluded. Provisional scores may change after review.	Buy Now
3	TB-500 5 mgUK Peptides (ukpeptides.com)	5 mg / vial	£39.99per vial	£8.00per mg	Testing evidence Evidence status Testing claimed Manufacturer statement "Specifications for this compound, independently verified by HPLC and LC-MS before release."; "99{4126ccafc2fa8f847ceaeb6a91497cc67cd381373337e0df85dd9df95f3d94fa}+ HPLC verified"; "Every batch is sent to an independent accredited lab for HPLC purity and LC-MS identity testing before it's released." Laboratory Not recorded Certification body Not recorded Batch Not recorded Batch-specific report Not established in this record Report date Not recorded Evidence checked 2026-09-20	Why this score? Testing & analytical evidence 10/45 Value 7/25 Product identity 12/15 Supplier transparency 3/10 Label & listing transparency 5/5 Displayed points and weights are rounded; the total uses unrounded weights. Pending dimensions are excluded. Provisional scores may change after review.	Buy Now
4	TB500 Theymalin Beta-4 5 mgUK Peptides (ukpeptides.com)	5 mg / vial	£39.99per vial	£8.00per mg	Testing evidence Evidence status Testing claimed Manufacturer statement "96.7{4126ccafc2fa8f847ceaeb6a91497cc67cd381373337e0df85dd9df95f3d94fa} HPLC purity · batch COA"; "Specifications for this compound, independently verified by HPLC and LC-MS before release."; "99{4126ccafc2fa8f847ceaeb6a91497cc67cd381373337e0df85dd9df95f3d94fa} purity guarantee" Laboratory Not recorded Certification body Not recorded Batch Not recorded Batch-specific report Not established in this record Report date Not recorded Evidence checked 2026-09-20	Why this score? Testing & analytical evidence 10/45 Value 7/25 Product identity 11/15 Supplier transparency 3/10 Label & listing transparency 5/5 Displayed points and weights are rounded; the total uses unrounded weights. Pending dimensions are excluded. Provisional scores may change after review.	Buy Now

Quantity: 5 mg / vial

£4.80per mg

£23.99per pack

View Analysis Buy Now

Product & testing details

Supplier: UK Peptides (ukpeptides.org)
Vials per pack: 1
Price per vial: £23.99
Listing last checked: 2026-09-20 09:20:11

Evidence status: Manufacturer COA
Manufacturer statement: Independent third-party laboratory report for batch UKP-TB500-2511 of TB-500 5mg, issued by an accredited independent laboratory using HPLC-UV + Mass Spectrometry. Result: ≥98{4126ccafc2fa8f847ceaeb6a91497cc67cd381373337e0df85dd9df95f3d94fa} HPLC.
Laboratory: Not recorded
Certification body: Not recorded
Batch: UKP-TB500-2511
Batch-specific report: Recorded
Report date: 2025-11-25
Evidence checked: 2026-09-20

Certificate of analysis ↗

Quantity: 10 mg / vial

£2.50per mg

£25.00per pack

View Analysis Buy Now

Product & testing details

Supplier: Reta Research
Vials per pack: 1
Price per vial: £25.00
Listing last checked: 2026-09-20 09:20:11

Evidence status: Testing claimed
Manufacturer statement: Lyophilised powder, 10mg vial, ≥99{4126ccafc2fa8f847ceaeb6a91497cc67cd381373337e0df85dd9df95f3d94fa} purity by HPLC, Certificate of Analysis on request. UK-based dispatch for preclinical research only.
Laboratory: Not recorded
Certification body: Not recorded
Batch: Not recorded
Batch-specific report: Not established in this record
Report date: Not recorded
Evidence checked: 2026-09-20

Quantity: 5 mg / vial

£8.00per mg

£39.99per pack

View Analysis Buy Now

Product & testing details

Supplier: UK Peptides (ukpeptides.com)
Vials per pack: 1
Price per vial: £39.99
Listing last checked: 2026-09-20 09:20:11

Evidence status: Testing claimed
Manufacturer statement: "Specifications for this compound, independently verified by HPLC and LC-MS before release."; "99{4126ccafc2fa8f847ceaeb6a91497cc67cd381373337e0df85dd9df95f3d94fa}+ HPLC verified"; "Every batch is sent to an independent accredited lab for HPLC purity and LC-MS identity testing before it's released."
Laboratory: Not recorded
Certification body: Not recorded
Batch: Not recorded
Batch-specific report: Not established in this record
Report date: Not recorded
Evidence checked: 2026-09-20

Quantity: 5 mg / vial

£8.00per mg

£39.99per pack

View Analysis Buy Now

Product & testing details

Supplier: UK Peptides (ukpeptides.com)
Vials per pack: 1
Price per vial: £39.99
Listing last checked: 2026-09-20 09:20:11

Evidence status: Testing claimed
Manufacturer statement: "96.7{4126ccafc2fa8f847ceaeb6a91497cc67cd381373337e0df85dd9df95f3d94fa} HPLC purity · batch COA"; "Specifications for this compound, independently verified by HPLC and LC-MS before release."; "99{4126ccafc2fa8f847ceaeb6a91497cc67cd381373337e0df85dd9df95f3d94fa} purity guarantee"
Laboratory: Not recorded
Certification body: Not recorded
Batch: Not recorded
Batch-specific report: Not established in this record
Report date: Not recorded
Evidence checked: 2026-09-20

What is TB-500?

TB-500 is a short synthetic peptide corresponding to the N-terminally acetylated 17–23 fragment of thymosin beta-4. Its seven-amino-acid sequence is Ac-LKKTETQ. [S1][S2] That distinction matters: TB-500 is not the same thing as full-length thymosin beta-4, a 43-amino-acid protein with a much larger research literature. [S5][S6] Much of the evidence commonly attributed online to TB-500 actually comes from full-length thymosin beta-4, related short fragments or animal studies rather than direct human TB-500 trials.

TB-500, full-length thymosin beta-4 and other thymosin-derived fragments must not be treated as interchangeable interventions. [S2][S5][S6]

What does the TB-500 research actually show?

Direct TB-500 evidence is much smaller than the broader thymosin beta-4 literature. A 2026 scoping review identified 80 thymosin beta-4/TB-500 studies but found that most concerned full-length thymosin beta-4; through its March 2026 search cutoff, direct TB-500 evidence was extremely sparse. [S5] Since that cutoff, a July 2026 rat Achilles-tendon study reported favourable biomechanical and histological findings with TB-500, but it remained an exploratory animal study. [S7] A 2024 metabolism study also found that parent TB-500 itself did not significantly accelerate a fibroblast scratch-assay model, while one metabolite, Ac-LKKTE, did. [S4] FDA's July 2026 review said it had not identified published human clinical studies or human exposure data for TB-500. [S8]

Direct TB-500 evidence

Direct published evidence is mainly laboratory and animal work. The current evidence base is far smaller than the literature on full-length thymosin beta-4.

Mostly preclinical

Achilles-tendon model

A 2026 rat study reported higher load to failure and better histological scores with TB-500 after surgically repaired Achilles injury.

Animal study

Wound-assay result

In a 2024 fibroblast scratch assay, parent TB-500 did not show significant wound-closure activity, while the metabolite Ac-LKKTE did.

Laboratory finding

Human evidence

FDA's 2026 review found no published clinical studies or human exposure data for TB-500 itself.

No direct human trial evidence identified

Research area	What was studied	Evidence level
Tendon repair	Surgically repaired Achilles tendons in rats	Animal evidence
Wound closure / metabolism	Fibroblast scratch assay plus rat metabolism work	Laboratory and animal evidence
Human clinical effects	No published TB-500 patient studies identified by FDA in its 2026 review	Evidence gap
Full-length thymosin beta-4	Human wound, ocular and healthy-volunteer studies	Human evidence, but for a different molecule

The July 2026 Achilles study was published after the March 2026 search cutoff of the main scoping review, so both sources are needed to describe the current direct evidence. [S5][S7]

TB-500 vs thymosin beta-4: why the distinction matters

Full-length thymosin beta-4 contains 43 amino acids, whereas TB-500 is the N-acetylated seven-amino-acid 17–23 fragment Ac-LKKTETQ. [S2][S5] The LKKTET region is associated with actin binding in thymosin beta-4 biology, but a short fragment does not automatically reproduce every property, exposure pattern or clinical effect of the full-length protein. [S16][S17] This is especially important because full-length thymosin beta-4 has been studied in healthy volunteers, venous ulcers and ophthalmic trials, while comparable direct human TB-500 trials have not been established. [S11][S12][S13][S14]

Material	What it is	How the evidence should be used
TB-500	N-acetylated 17–23 fragment, Ac-LKKTETQ	Direct TB-500 evidence only
Thymosin beta-4	Full-length 43-amino-acid protein	Parent-protein evidence; not automatically transferable to TB-500
LKKTETQ-related fragments	Related short peptide sequences with different terminal chemistry or length	Mechanistic context only unless the exact fragment matches
Other thymosin products	Different formulations or derivatives	Keep separate unless chemical identity is verified

A human study of full-length thymosin beta-4 should never be labelled as a human TB-500 study.

TB-500 and tendon healing: what did the 2026 rat study find?

The most directly relevant recent musculoskeletal study used 32 male Sprague-Dawley rats after Achilles-tendon transection and repair. [S7] Animals were allocated to control, BPC-157, TB-500 or combination groups. The TB-500 group received 60 micrograms per kilogram per day intraperitoneally for 30 days. At the study endpoint, TB-500-treated tendons had a significantly higher maximum load to failure than controls and better Bonar and Movin histology scores. [S7] The combination group did not show an additional benefit over either peptide alone. These findings are preliminary animal data, not evidence of tendon healing in people.

Biomechanics

The TB-500 group had a significantly higher maximum load to failure than the untreated control group at the study endpoint.

Rat model

Histology

Bonar and Movin scores were significantly lower in the TB-500 group than controls, consistent with improved histological appearance in this model.

Rat model

Important limitation

Only four tendons per group were used for biomechanical testing and four per group for histology, with one endpoint and no human participants.

Exploratory study

The paper describes the tested material as TB-500/synthetic thymosin beta-4 sourced commercially, but the visible report does not independently characterise every product-specification detail. Do not assume all products labelled TB-500 are equivalent.

Has TB-500 been studied in humans?

No credible published human efficacy or safety trial of TB-500 itself was identified in the evidence reviewed. FDA's July 2026 evaluation stated that it found no medical-literature reports in which TB-500 was administered to patients for any disease or condition and no human exposure data by any route. [S8][S9] Human studies do exist for full-length thymosin beta-4, including intravenous dosing in healthy volunteers, topical venous-ulcer research and ophthalmic trials. [S11][S12][S13][S14] Those studies can provide context about the parent protein, but they do not establish TB-500 efficacy, safety, dose or pharmacokinetics.

TB-500 itself

No published patient trial or human exposure study was identified by FDA in its 2026 review.

Direct human evidence absent

Full-length thymosin beta-4

Human trials exist in healthy volunteers, venous ulcers and dry-eye research, but this is a different 43-amino-acid molecule.

Different molecule

Do not use full-length thymosin beta-4 human trial doses, half-lives or safety findings as if they had been measured for TB-500.

Wound healing: direct TB-500 data versus parent-protein research

Wound healing is a common TB-500 search theme, but direct fragment evidence is limited. In the 2024 study that examined TB-500 metabolism and fibroblast wound-closure activity, the parent peptide did not significantly promote closure in the in-vitro scratch assay, while the metabolite Ac-LKKTE did. [S4] By contrast, full-length thymosin beta-4 has a broader wound-repair literature, including a randomised venous-ulcer study that reported a healing signal at one topical concentration. [S13] That parent-protein result should not be relabelled as TB-500 evidence.

Parent TB-500

No significant wound-closure effect in the 2024 fibroblast scratch assay.

In-vitro finding

TB-500 metabolite

Ac-LKKTE showed wound-closure activity in the same screening work, suggesting that metabolism may matter to biological activity.

In-vitro finding

Full-length Tβ4

Human wound studies exist for the parent protein, but the molecule and formulation are not TB-500.

Different molecule

A positive result for a metabolite or full-length thymosin beta-4 does not prove that administered TB-500 has the same clinical effect.

TB-500 with BPC-157: what has actually been tested?

TB-500 and BPC-157 are often discussed together online, but controlled evidence for the combination is minimal. The 2026 rat Achilles study directly compared control, BPC-157, TB-500 and a combination. [S7] Both single-peptide groups showed favourable findings in that model, but the combination did not produce an additional biomechanical or histological advantage over either peptide alone. No controlled human combination trial was identified in the sources reviewed.

This animal study does not establish a human 'stack', dose or administration protocol.

TB-500 half-life and pharmacokinetics

A validated human TB-500 half-life has not been established. FDA's 2026 review cited an equine study in which plasma concentrations peaked about one to two hours after subcutaneous administration and became unquantifiable after roughly six to ten hours. [S3][S8] A separate 2024 rat metabolism study detected some acetylated metabolites in urine for much longer, including Ac-LKK for up to 72 hours. [S4] Neither finding should be converted into a human half-life.

Horse plasma detection, rat metabolite detection and human pharmacokinetics are different questions.

TB-500 dosage in research: what has actually been studied?

There is no established human TB-500 research dose because direct human exposure studies were not identified. [S8][S9] The literature instead contains animal and laboratory protocols. These can describe what researchers did, but they must not be converted into consumer dosing guidance.

Research context	Protocol detail reported	What it means
Rat Achilles-tendon study	60 micrograms/kg/day intraperitoneally for 30 days	Animal tendon-repair protocol only
Equine doping-detection study	Single 10 mg subcutaneous administration	Horse pharmacokinetic/detection study only
Human TB-500 studies	No verified clinical dose identified	No human research dose can be established from the reviewed evidence

Do not convert animal doses by body weight, surface area or any other method. Do not provide reconstitution or injection instructions.

Side effects and safety: what is actually known?

Reliable human side-effect frequencies cannot be given because published human TB-500 exposure data were not identified. FDA's 2026 review said the potential human safety risks are unknown and found no nonclinical toxicology studies adequate to characterise risk. [S8] FDA also lists TB-500 among bulk substances that may pose significant safety risks in compounding, highlighting potential immunogenicity from peptide aggregation and peptide-related impurities. [S9] The absence of adverse-event reports in passive reporting systems does not demonstrate safety, especially when exposure itself is uncertain.

Human safety data

No published human exposure dataset was identified by FDA for TB-500 itself.

Major evidence gap

Immunogenicity

FDA highlights possible immune reactions related to peptide aggregation and impurities in injectable compounded products.

Regulatory concern

Toxicology

FDA's 2026 assessment did not identify a sufficient nonclinical toxicology package to characterise potential human risk.

Evidence gap

Do not invent a list of 'common TB-500 side effects'. The direct human evidence is too limited to support reliable frequencies.

TB-500 and competitive sport

The World Anti-Doping Agency's 2026 Prohibited List explicitly names thymosin beta-4 and its derivatives, including TB-500, under section S2.3 Growth Factors and Growth Factor Modulators. [S10] Substances in S2 are prohibited at all times, both in and out of competition. Athletes subject to WADA rules should therefore treat TB-500 as a prohibited substance.

This is an anti-doping rule, not evidence about efficacy or safety.

Registered TB-500 trials: one important integrity warning

ClinicalTrials.gov currently contains a TB-500-labelled record, NCT07487363, but it is not a genuine efficacy trial. The record's own brief summary explicitly says: 'This fictional study is an example of a ClinicalTrials.gov-style record.' [S15] It therefore must not be cited as evidence that a Phase 1/2 TB-500 cardiovascular study is genuinely recruiting. Full-length thymosin beta-4 has legitimate registered human trials such as ARISE-2 in dry eye, but those studies concern the parent protein rather than TB-500. [S14]

Registry record	What the registry says	Editorial treatment
NCT07487363	Displayed as a Phase 1/2 TB-500 ASCVD study, but the official summary states it is fictional	Do not count as a real TB-500 trial
NCT02974907	Completed Phase 3 dry-eye study of RGN-259	Legitimate full-length thymosin beta-4 context, not TB-500 evidence

Trial registration is not evidence that a treatment works; in this case the direct TB-500-labelled record is explicitly fictional.

How to compare TB-500 research products

When product records are added later, the comparison should focus on verifiable product facts rather than claimed recovery outcomes. Labelled quantity and pack price allow price per mg to be calculated consistently. Testing evidence should distinguish independently verifiable laboratory reports from manufacturer COAs, unsupported claims and cases where no evidence was located. Identity matters particularly for TB-500 because full-length thymosin beta-4, unacetylated fragments and other thymosin-derived peptides are not interchangeable with Ac-LKKTETQ. [S1][S2]

Exact identity

The research definition is the N-acetylated seven-amino-acid fragment Ac-LKKTETQ. Do not silently treat full-length thymosin beta-4 as the same product.

Labelled quantity

Record the stated amount per vial or unit and keep pack totals separate.

Price per mg

Use a consistent labelled-quantity basis across products rather than a claimed human dose.

Testing evidence

Separate independent laboratory evidence, manufacturer COAs, unsupported testing claims and cases where no public evidence was located.

Compound-level research does not verify the identity, purity or safety of a particular third-party product.

Frequently asked questions

What is TB-500?

TB-500 is the N-terminally acetylated 17–23 fragment of thymosin beta-4. It is a seven-amino-acid peptide with the sequence Ac-LKKTETQ.

Is TB-500 the same as thymosin beta-4?

No. TB-500 is a seven-amino-acid fragment, while full-length thymosin beta-4 contains 43 amino acids. Human studies of full-length thymosin beta-4 should not be presented as human TB-500 studies.

What benefits of TB-500 are supported by research?

Direct evidence is mainly preclinical. A 2026 rat Achilles-tendon study reported favourable biomechanical and histological findings, while a 2024 fibroblast scratch assay found no significant wound-closure activity for parent TB-500 itself. There is no established human efficacy evidence for TB-500.

Has TB-500 been studied in humans?

FDA's 2026 evaluation reported that it had not identified published clinical studies or human exposure data for TB-500 itself. Human studies exist for full-length thymosin beta-4, which is a different molecule.

Does TB-500 help tendon healing?

A 2026 rat Achilles-tendon study reported improved maximum load to failure and histological scores with TB-500. The study was exploratory, used small numbers per endpoint and involved rats, so it does not establish tendon-healing effects in people.

What is the half-life of TB-500?

A validated human TB-500 half-life has not been established. An equine study found plasma concentrations peaked about one to two hours after administration and became unquantifiable after roughly six to ten hours, but horse data should not be presented as a human half-life.

What doses of TB-500 have been studied?

No verified human TB-500 dose was identified. Animal research has used study-specific protocols, including 60 micrograms/kg/day in a rat Achilles-tendon study and a single 10 mg administration in an equine detection study. These are animal research methods, not human dosing guidance.

What side effects does TB-500 cause?

Reliable human side-effect frequencies are not available because published human exposure data are lacking. FDA highlights unknown human safety, limited toxicology information and possible immunogenicity risks from peptide aggregation and impurities in injectable compounded products.

What is the evidence for TB-500 and BPC-157 together?

A 2026 rat Achilles-tendon study tested both peptides alone and together. The combination did not show an additional advantage over the individual peptide groups in that model. No controlled human combination trial was identified.

Is TB-500 banned in sport?

Yes under WADA rules. The 2026 Prohibited List explicitly names thymosin beta-4 and its derivatives, including TB-500, under S2.3. S2 substances are prohibited at all times.

Is the TB-500 ClinicalTrials.gov cardiovascular study real?

No. NCT07487363 is displayed in a ClinicalTrials.gov-style format, but its own official summary explicitly states that it is a fictional example study. It should not be counted as a genuine TB-500 clinical trial.

Why compare TB-500 products by price per mg rather than price per dose?

There is no established human TB-500 dose in the evidence reviewed. Price per mg compares labelled quantities without turning animal or laboratory research protocols into consumer dosing advice.

Sources & methodology

We separate animal models, observational human studies and ongoing trials. Scientific evidence is assessed independently of future supplier documentation. How we verify testing →

Page updated: 19 September 2026Sources checked: 19 September 2026

Testing evidence in this comparison

Manufacturer COA: 1
Testing claimed: 3

What does TB-500 cost?

Lowest: £2.50 / mg · Median: £6.40 / mg · Highest: £8.00 / mg

TB-500 Research Peptides

Top Picks

Best Overall

TB-500 5mgUK Peptides (ukpeptides.org)

TB-500 5mg

Best Tested

TB-500 5mgUK Peptides (ukpeptides.org)

TB-500 5mg

Lowest Price per mg

TB-500 10mgReta Research

TB-500 10mg

Compare research products

TB-500 5mgUK Peptides (ukpeptides.org)

TB-500 10mgReta Research

TB-500 5 mgUK Peptides (ukpeptides.com)

TB500 Theymalin Beta-4 5 mgUK Peptides (ukpeptides.com)

What is TB-500?

What does the TB-500 research actually show?

Direct TB-500 evidence

Achilles-tendon model

Wound-assay result

Human evidence

TB-500 vs thymosin beta-4: why the distinction matters

TB-500 and tendon healing: what did the 2026 rat study find?

Biomechanics

Histology

Important limitation

Has TB-500 been studied in humans?

TB-500 itself

Full-length thymosin beta-4

Wound healing: direct TB-500 data versus parent-protein research

Parent TB-500

TB-500 metabolite

Full-length Tβ4

TB-500 with BPC-157: what has actually been tested?

TB-500 half-life and pharmacokinetics

TB-500 dosage in research: what has actually been studied?

Side effects and safety: what is actually known?

Human safety data

Immunogenicity

Toxicology

TB-500 and competitive sport

Registered TB-500 trials: one important integrity warning

How to compare TB-500 research products

Exact identity

Labelled quantity

Price per mg

Testing evidence

Frequently asked questions

Sources & methodology

Testing evidence in this comparison

What does TB-500 cost?